INTRODUCTION AND OBJECTIVES: The effects of industry payments to physicians on prescribing habits are not well understood. We aimed to determine the association between the receipt of industry payments and the prescribing of alpha-blockers and overactive bladder (OAB) medications.
METHODS: The Open Payments Program (OPP) database and Medicare Part D claims database for 2014 were linked. This provided industry payment information and prescription information for individual physicians in the US. We identified all physicians who prescribed any alpha-blocker or OAB drug. We also identified actively promoted drug (based on payments) within each group. Silodosin was the only actively promoted alpha-blocker. Fesoterodine, solifenacin, and mirabegron were the actively promoted OAB drugs. For each promoted drug, we calculated the proportion of physicians who 00 preferred 00 the promoted drug, i.e. prescribed the promoted drug more often than all other drugs in that class combined. Regression analysis was performed to quantify the effect of industry payment on 00 preferred 00 prescribing. Analysis was conducted for any payment, greater than the median payment, and high payment (>$100). Prescribing physicians were categorized as urologists or non-urologists.
RESULTS: In 2014, among the 108,680 physicians who prescribed an alpha blocker or an overactive bladder medication through Medicare Part D, 66,726 received at least one industry payment by the manufacturer of that drug. For each promoted drug, physicians who received any payment from its manufacturer prescribed that drug more often, relative to all drugs in its class. Receipt of payment from the promoting company was associated with significantly increased odds of preferentially prescribing that drug (Table 1) . This effect was significant when considering all physicians and non-urologists. However, when considering urologists alone, no significant effect was noted. Sensitivity analyses conducted using median payment and high payment thresholds confirmed these findings.
CONCLUSIONS: Receipt of industry payment is associated with increased prescribing of promoted urologic drugs. This effect varies according to specialty, possibly reflecting the strength of established prescribing patterns or close familiarity with these drugs for urologists as compared to other physicians. 
INTRODUCTION AND OBJECTIVES:
In the United States, the most common presentation for penile cancer (PC) is a distal, organ confined squamous cell cancer. Traditional treatment of PC in the form of total penectomy (TP) carries devastating functional and psychological outcomes. There is evidence that organ sparing surgery (OSS) has a higher rate of recurrence though that may not impact survival. We utilize the national cancer database to asses for a difference in survival among the different surgical options commonly used to treat T1/T2 penile cancer.
METHODS: Patients underwent OSS, partial penectomy (PP) and TP were identified. Demographic data including differences among the 3 groups were assessed using Chi-square test. Survival estimates were assessed using Kaplan-Meier estimate.
RESULTS: Between 2004 and 2014, 1,539 patients underwent surgery for T1/T2 penile cancer. There were 477 patients in the OSS group, 802 in the PP group and 202 in the TP group. Mean follow up in months was 44.6, 41.6 and 38.4 in the OSS, PP and TP groups respectively (p¼0.002). There was no difference in age or racial distribution among the 3 groups (p¼0.75 and 0.54 respectively). Overall, the three groups were more likely to receive treatment in an academic center, Medicare was the prevailing insurance type and most patients reside in Urban areas (p¼<0.001, <0.001 and 0.04 respectively). The incidence of T1/T2 in the OSS, PP and TP groups were 85.9/14.1, 39.8/ 50.2 and 37.7/62.3 respectively (p¼ <0.001). The 1,5 and 10 years survival rates for the 3 groups is illustrated in Table 1 . Predictors of poor survival were older age, black race and T2 disease. The type of surgery offered was not predictor of poor survival.
CONCLUSIONS: In the early stage penile cancer, which is the most common presenting stage in the United States, the degree of aggressiveness of initial surgical treatment did not alter the long term patient survival. Consideration for penile organ sparing surgery, which has better functional and psychological outcomes, should always be discussed with the patient. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e929
